Related Experiment Video
Updated: Jun 28, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Spirooxadiazoline-oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells
Liviane D de Azevedo1, Debora I Leite1, Andressa P de Oliveira1
1Departamento de Síntese Orgânica, Fundação Oswaldo Cruz, Farmanguinhos, Rio de Janeiro, Brasil.
Abstract:
Imatinib mesylate was the first representative BCR-ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this pathology, a resistance mechanism occurs against all BCR-ABL1 inhibitors, necessitating a constant search for new therapeutic options. To develop new antimyeloproliferative substances, we applied a medicinal chemistry tool known as molecular hybridization to design 25 new substances. These compounds were synthesized and biologically evaluated against K562 cells, which express BCR-ABL1, a constitutively active tyrosine kinase enzyme, as well as in WSS-1 cells (healthy cells). The new compounds are conjugated hybrids that contain phenylamino-pyrimidine-pyridine (PAPP) and an isatin backbone, which are the main pharmacophoric fragments of imatinib and sunitinib, respectively. A spiro-oxindole nucleus was used as a linker because it occurs in many compounds with antimyeloproliferative activity. Compounds 2a, 2b, 3c, 4c, and 4e showed promise, as they inhibited cell viability by between 45% and 61% at a concentration of 10 µM. The CC50 of the most active substances was determined to be within 0.8-9.8 µM.
Insights
Researchers developed novel hybrid compounds targeting BCR-ABL1 tyrosine kinase inhibitors for chronic myeloid leukemia treatment. Some compounds demonstrated significant antimyeloproliferative activity, inhibiting cancer cell viability.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Imatinib mesylate, a BCR-ABL1 tyrosine kinase inhibitor (TKI), revolutionized chronic myeloid leukemia (CML) treatment.
- Resistance to existing TKIs necessitates the development of new therapeutic agents.
- BCR-ABL1 is a constitutively active tyrosine kinase enzyme driving CML proliferation.
Purpose of the Study:
- To design and synthesize novel antimyeloproliferative substances.
- To develop new therapeutic options for CML by overcoming TKI resistance.
- To explore molecular hybridization for creating drug candidates.
Main Methods:
- Molecular hybridization was employed to design 25 new chemical entities.
- Synthesized compounds were evaluated for biological activity against K562 (CML) and WSS-1 (healthy) cells.
- Compounds featured phenylamino-pyrimidine-pyridine (PAPP) and isatin fragments linked by a spiro-oxindole nucleus.
Main Results:
- Compounds 2a, 2b, 3c, 4c, and 4e exhibited significant inhibition of cell viability (45-61%) at 10 µM against K562 cells.
- The CC50 (median cytotoxic concentration) of the most potent compounds ranged from 0.8 to 9.8 µM.
- The novel hybrids demonstrated promising antimyeloproliferative activity.
Conclusions:
- The designed hybrid compounds represent potential new therapeutic agents for CML.
- Molecular hybridization is an effective strategy for developing novel antimyeloproliferative substances.
- Further investigation into these compounds may lead to improved CML treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...